scispace - formally typeset
F

François Sellal

Researcher at University of Strasbourg

Publications -  154
Citations -  3887

François Sellal is an academic researcher from University of Strasbourg. The author has contributed to research in topics: Dementia & Medicine. The author has an hindex of 30, co-authored 127 publications receiving 3182 citations. Previous affiliations of François Sellal include French Institute of Health and Medical Research & Aix-Marseille University.

Papers
More filters
Journal ArticleDOI

Penumbral imaging and functional outcome in patients with anterior circulation ischaemic stroke treated with endovascular thrombectomy versus medical therapy: a meta-analysis of individual patient-level data

Bruce C.V. Campbell, +1296 more
- 01 Jan 2019 - 
TL;DR: Estimated ischaemic core volume was independently associated with functional independence and functional improvement but did not modify the treatment benefit of endovascular thrombectomy over standard medical therapy for improved functional outcome.
Journal ArticleDOI

Cannabis Use, Ischemic Stroke, and Multifocal Intracranial Vasoconstriction A Prospective Study in 48 Consecutive Young Patients

Valérie Wolff, +10 more
- 01 Jun 2011 - 
TL;DR: Multifocal angiopathy associated with cannabis consumption could be an important cause of ischemic stroke in young people.
Journal ArticleDOI

Demographic, neurological and behavioural characteristics and brain perfusion SPECT in frontal variant of frontotemporal dementia

Isabelle Le Ber, +26 more
- 01 Nov 2006 - 
TL;DR: This study shows that fvFTD is clinically a rather homogeneous entity and provides evidence that different behavioural presentations at onset are related to different anatomical localizations of degenerative damage, and demonstrates the prognostic value of brainstem hypoperfusion in a subgroup of patients with a short survival.
Journal ArticleDOI

Progranulin null mutations in both sporadic and familial frontotemporal dementia.

Isabelle Le Ber, +24 more
- 01 Sep 2007 - 
TL;DR: It is supported that PGRN null mutations represent a more frequent cause of FTD than MAPT mutations but are not responsible for FTD‐MND, and genetic testing should be considered more systematically, even in patients without obvious familial history ofFTD.
Journal ArticleDOI

Doxycycline in Creutzfeldt-Jakob disease: a phase 2, randomised, double-blind, placebo-controlled trial.

Stéphane Haïk, +36 more
- 01 Feb 2014 - 
TL;DR: Doxycycline at a dose of 100 mg per day was well tolerated but did not significantly affect the course of CJD, at variance with the results of previous observational studies.